Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers
Clinical Validation of an Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Indicating Cognitive Decline
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic Arizona
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients older than 18 years and diagnosed with mild cognitive impairment (MCI), Alzheimer's disease (AD), or vascular cognitive impairment and/or dementia (VaD).
Exclusion Criteria:
- Children and subjects with other diagnoses than those mentioned in the inclusion criteria.
- Patients without the means to visit the clinic on the assigned dates.
- Patients who are pregnant or are expecting to become pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Cognitive diagnosis
|
Fundus photographs
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
retinopathy features identification
Time Frame: 12 months
|
The retinal vascular parameters computed using EyeQuant will be compared against the current gold-standard, based on expert annotations
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Oana Dumitrascu, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dementia
- Tauopathies
- Cognition Disorders
- Intracranial Arterial Diseases
- Intracranial Arteriosclerosis
- Leukoencephalopathies
- Alzheimer Disease
- Cognitive Dysfunction
- Dementia, Vascular
Other Study ID Numbers
Other Study ID Numbers
- 20-007289
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
NCT04100889WithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5
-
NCT05637801Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia
-
NCT07573982Not yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s Disease
-
NCT06597942RecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s Dementia
-
NCT03806478Not yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
NCT07564700Not yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)
-
NCT07459959Not yet recruiting
-
NCT07208734Enrolling by invitationAlzheimer s Disease
-
NCT07367880Recruiting
-
NCT07324161Recruiting
Clinical Trials on Retinal fundus photography
-
NCT06924021RecruitingAge-Related Macular Degeneration
-
NCT05286502CompletedFundus Photography
-
NCT03076697Enrolling by invitationGlaucoma | Diabetes Mellitus | Diabetic Retinopathy | Age Related Macular Degeneration | Retinal Disease | ROP
-
NCT02089893CompletedCilioretinal Arteries
-
NCT01625598CompletedDiabetic Retinopathy
-
NCT06423274Not yet recruitingDiabetic Retinopathy | Diabetic Macular Edema
-
NCT07244640RecruitingParkinson's Disease (PD)